ST香雪: 关于涉及重大诉讼案进展的公告

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. is involved in a legal dispute with Hubei Qingsong Yuyue Pharmaceutical Co., Ltd. regarding loan repayment, with a court ruling mandating repayment of principal and interest, which the company is actively addressing to protect its interests [1][2]. Group 1: Legal Judgment Details - The court ordered Hubei Qingsong Yuyue Pharmaceutical Co., Ltd. to repay a principal amount of 81.2 million yuan and interest calculated at a rate of 14.6% until the actual repayment date [1]. - Additionally, the company is required to pay 4 million yuan in principal and associated interest, along with 600,000 yuan in legal fees [1]. - The ruling grants the plaintiff, Hubei Qingsong Yuyue Pharmaceutical Co., Ltd., a priority right to the proceeds from the pledged shares of Hubei Tianji Pharmaceutical Co., Ltd. valued at 60 million yuan [1]. Group 2: Impact on the Company - The company is in active communication with Hubei Qingsong Yuyue Pharmaceutical Co., Ltd. to seek a resolution to the dispute, aiming to safeguard the interests of the company and its shareholders [2]. - The ongoing litigation is not expected to have a significant impact on the company's production operations or financial status [2]. - The company has pledged its shares in Hubei Tianji Pharmaceutical Co., Ltd. as part of the legal proceedings [2].